RAS pathway mutations have been linked to relapse and chemotherapy resistance in
pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However …

Abstract Background: The 5-year event-free survival of pediatric precursor-B acute
lymphoblastic leukemia (BCP-ALL) has currently reached 80-90%. Targeted drugs are …

Highlights•B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is currently treated by
risk-adapted intensive chemotherapy•Genome-wide genomic analyses have uncovered the …

Recent genetic studies using high-throughput sequencing have disclosed genetic
alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects …

Somatic genetic abnormalities are initiators and drivers of disease and have proven clinical
utility at initial diagnosis. However, the genetic landscape and its clinical utility at relapse are …

We sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute
lymphoblastic leukemias, the largest pediatric cancer genome sequencing effort reported to …

To characterize the mutational patterns of acute lymphoblastic leukemia (ALL) we performed
deep next generation sequencing of 872 cancer genes in 172 diagnostic and 24 relapse …

Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high
frequency of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1 …

To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute
lymphoblastic leukemia (ALL), a clinically defined poor-risk group with few known recurring …

Most B cell precursor acute lymphoblastic leukemia (BCP ALL) can be classified into known
major genetic subtypes, while a substantial proportion of BCP ALL remains poorly …